Nevro (NVRO) to Release Quarterly Earnings on Wednesday

Nevro (NYSE:NVRO) will likely be announcing its earnings results after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $100.02 million for the quarter.

Nevro (NYSE:NVRO) last released its earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.40. The firm had revenue of $96.60 million during the quarter, compared to analysts’ expectations of $93.09 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. Nevro’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.65) EPS. On average, analysts expect Nevro to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nevro Price Performance

NVRO stock opened at $5.72 on Wednesday. The business’s 50-day moving average is $4.32 and its two-hundred day moving average is $5.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. The firm has a market capitalization of $214.33 million, a P/E ratio of -3.03 and a beta of 0.91. Nevro has a 1 year low of $3.16 and a 1 year high of $17.75.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Nevro from $4.00 to $5.85 and gave the company a “hold” rating in a report on Friday, February 7th. Truist Financial decreased their price target on Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a report on Wednesday, December 18th. StockNews.com upgraded shares of Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th. Morgan Stanley cut Nevro from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $9.00 to $4.00 in a research report on Monday, December 2nd. Finally, Piper Sandler raised shares of Nevro from a “neutral” rating to an “overweight” rating and lowered their price objective for the stock from $6.00 to $5.85 in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.